alpha-D-glucose : D-Glucopyranose having alpha-configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
(1->6)-alpha-D-glucan : An alpha-D-glucan in which the glucose units are connected by (1->6) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
(1->3)-alpha-D-glucan : An alpha-D-glucan in which the glucose units are connected by (1->3) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 79025 |
| CHEMBL ID | 423707 |
| CHEBI ID | 17925 |
| CHEBI ID | 18269 |
| CHEBI ID | 28102 |
| CHEBI ID | 15444 |
| CHEBI ID | 18398 |
| CHEBI ID | 28100 |
| SCHEMBL ID | 6222 |
| MeSH ID | M0009339 |
| Synonym |
|---|
| AC-15067 |
| CHEMBL423707 , |
| unii-5j5i9eb41e |
| einecs 207-757-8 |
| 5j5i9eb41e , |
| alpha-dextrose |
| alpha-d-glc |
| CHEBI:17925 , |
| d-(+)-glucose, meets analytical specification of ph. eur., bp, anhydrous |
| corn sugar |
| glucopyranose, alpha-d- |
| (+)-glucose |
| cmc_6867 |
| alpha-d-glucose |
| (1,4-alpha-d-glucosyl)n |
| (1,6-alpha-d-glucosyl)n |
| 1,6-alpha-d-glucan |
| 1,3-alpha-d-glucan |
| 492-62-6 |
| C00267 |
| (1,4-alpha-d-glucosyl)n+1 |
| [alpha-d-glucosyl-(1,3)]n+1 |
| [alpha-d-glucosyl-(1,3)]n |
| 1,4-alpha-d-glucan |
| 4-{(1,4)-alpha-d-glucosyl}(n-1)-d-glucose |
| grape sugar |
| (1,4-alpha-d-glucosyl)n-1 |
| alpha-d-glucopyranose |
| ALPHA-GLUCOSE , |
| dextrin from corn, type i, powder |
| d-(+) glucose, analytical standard |
| d-(+)-glucose, hybri-max(tm), powder, bioreagent, suitable for hybridoma |
| dextrose, meets ep, bp, jp, usp testing specifications |
| dextrose, meets ep, bp, jp, usp testing specifications, anhydrous |
| dextrin from corn, commercial grade, type ii, powder |
| d-(+)-glucose, suitable for mouse embryo, >=99.5% (gc) |
| d-(+)-glucose, >=99.5% (gc) |
| d-(+)-glucose, plant cell culture tested, bioreagent |
| d-(+)-glucose, bioxtra, >=99.5% (gc) |
| d-(+)-glucose, powder, bioreagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99.5% |
| d-(+)-glucose, >=99% (gc) |
| d-(+)-glucose, analytical standard |
| NCGC00160621-01 |
| alpha-d-glucose, anhydrous, 96% |
| d(+)glucose, anhydrous |
| MOLMAP_000023 |
| CHEBI:18269 |
| (1->6)-alpha-d-glucan |
| d-(+)-glucose, bioultra, anhydrous, >=99.5% (sum of enantiomers, hplc) |
| 074AD9E3-1FC7-485C-8A50-2B653D501E5B |
| d-glucose-5-c-td-glucose [mesh: glucose] |
| d-gluose |
| d-gluco-hexose |
| glucoses |
| BMSE000015 |
| CHEBI:28102 |
| (1->4)-alpha-d-glucopyranan |
| CHEBI:15444 |
| (1->4)-alpha-d-glucan |
| (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol |
| NCGC00160621-03 |
| BMSE000797 |
| BMSE000855 |
| BMSE000791 |
| bdbm50351158 |
| AKOS015950677 |
| (2s,3r,4s,5s,6r)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol |
| EPITOPE ID:144998 |
| S6028 |
| WQZGKKKJIJFFOK-DVKNGEFBSA-N |
| smr004703328 |
| MLS006011570 |
| SCHEMBL6222 |
| glucosum, anhydrous [who-ip latin] |
| glucose, anhydrous [who-ip] |
| CHEBI:18398 |
| (1->3)-alpha-d-glucan |
| (1->3)-alpha-d-glucopyranan |
| CHEBI:28100 |
| 26655-34-5 |
| W-204032 |
| alpha-d-glucose, anhydrous |
| |a-d-glucose anhydrous |
| dextroseanhydrate |
| mfcd00063774 |
| d-(+)-glucose, anhydrous |
| DTXSID30197710 , |
| alpha-d(+)-glucose |
| dextrose, united states pharmacopeia (usp) reference standard |
| d-(+)-glucose, 99.9 atom % 16o, 99.9 atom % 12c |
| alpha-d-glucose, saj first grade, >=98.0% |
| d-(+)-glucose, tested according to ph.eur. |
| alpha-d-glucose, saj special grade, >=98.0% |
| glucose, european pharmacopoeia (ep) reference standard |
| alpha-delta-glucose |
| a-dextrose |
| alpha-delta-glucopyranose |
| a-glucose |
| a-d-glucose |
| a-d-glucopyranose |
| dextrose, pharmaceutical secondary standard; certified reference material |
| d-(+)-glucose, vetec(tm) reagent grade, >=99.5% |
| d-(+)-glucose, anhydrous, free-flowing, redi-dri(tm), >=99.5% |
| glucose, p.a., acs reagent |
| d-(+)-glucose, ar, anhydrous |
| dextrin from corn, p.a. |
| d-(+)-glucose, lr, anhydrous, >=99.5% |
| d-glucose (dextrose), nist(r) srm(r) 917c |
| (2s,3r,4s,5s,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol |
| 27707-45-5 |
| alpha-d-glucose; d-glucose; glucose |
| A871826 |
| HY-128417 |
| i+/--d-glucose |
| BS-17112 |
| Q23905965 |
| D70945 |
| alpha-d-glucopyranose, phase i |
| alpha-d-glucose, phase ii |
| alpha-d-glucose, phase i |
| alpha-d-glucopyranose, phase ii |
| CS-0099249 |
| alpha-d(+)-glucose, anhydrous |
| EN300-59169 |
| Z905052654 |
| Role | Description |
|---|---|
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| D-glucopyranose | A glucopyranose having D-configuration. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | Ki | 1,775.0000 | 0.0250 | 4.8903 | 9.0000 | AID1333322; AID1333327; AID453252; AID480616 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | Ki | 4,900.0000 | 0.4000 | 2.7500 | 5.1000 | AID1186739 |
| Glycogen phosphorylase, muscle form | Homo sapiens (human) | Ki | 1,700.0000 | 0.0040 | 3.4347 | 5.2000 | AID1186738 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| glycogen metabolic process | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| 5-phosphoribose 1-diphosphate biosynthetic process | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| response to bacterium | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| glucose homeostasis | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| necroptotic process | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| glycogen catabolic process | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| glycogen metabolic process | Glycogen phosphorylase, muscle form | Homo sapiens (human) |
| glycogen catabolic process | Glycogen phosphorylase, muscle form | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| cytosol | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| secretory granule lumen | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| extracellular exosome | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| ficolin-1-rich granule lumen | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| cytoplasm | Glycogen phosphorylase, liver form | Homo sapiens (human) |
| cytosol | Glycogen phosphorylase, muscle form | Homo sapiens (human) |
| extracellular exosome | Glycogen phosphorylase, muscle form | Homo sapiens (human) |
| cytoplasm | Glycogen phosphorylase, muscle form | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1698746 | Displacement of EtBr from calf thymus DNA incubated for 3 mins by fluorescence based assay | 2020 | Journal of natural products, 10-23, Volume: 83, Issue:10 | Synthesis and Stereochemical Assignment of Conioidine A: DNA- and HSA-Binding Studies of the Four Diastereomers. |
| AID1698748 | Binding affinity to calf thymus DNA assessed as change in melting temperature at DNA to ligand ratio at 40:1 by spectrophotometric method | 2020 | Journal of natural products, 10-23, Volume: 83, Issue:10 | Synthesis and Stereochemical Assignment of Conioidine A: DNA- and HSA-Binding Studies of the Four Diastereomers. |
| AID667422 | Competitive inhibition of rabbit skeletal muscle glycogen phosphorylase b using Glc-1-P as substrate | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | The binding of C5-alkynyl and alkylfurano[2,3-d]pyrimidine glucopyranonucleosides to glycogen phosphorylase b: synthesis, biochemical and biological assessment. |
| AID1333322 | Competitive inhibition of rabbit muscle glycogen phosphorylase-a in presence of varying levels of glucose-1-phosphate and constant concentration of glycogen by Hill plot analysis | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase. |
| AID480616 | Inhibition of rabbit muscle glycogen phosphorylase inactive form b | 2010 | Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10 | 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies. |
| AID1333327 | Inhibition of rabbit muscle glycogen phosphorylase-b after 1 min in presence of varying levels of glucose-1-phosphate and constant concentration of glycogen and AMP by double reciprocal plot method | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase. |
| AID453252 | Inhibition of rabbit muscle glycogen phosphorylase b | 2009 | Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20 | Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors. |
| AID28956 | Partition coefficient (logP) (dodecane) | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Rational determination of transfer free energies of small drugs across the water-oil interface. |
| AID28958 | Partition coefficient across water-dodecane interface by statistical simulation | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Rational determination of transfer free energies of small drugs across the water-oil interface. |
| AID614129 | Competitive inhibition of rabbit muscle glycogen phosphorylase b assessed as inorganic phosphate release using alphaD glucose-1-phosphate as substrate at pH 6.8 by spectrophotometric analysis | 2011 | Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17 | Halogen-substituted (C-β-D-glucopyranosyl)-hydroquinone regioisomers: synthesis, enzymatic evaluation and their binding to glycogen phosphorylase. |
| AID1333323 | Competitive inhibition of His6-tagged human liver glycogen phosphorylase-a expressed in Escherichia coli BL21 Gold (DE3) assessed as release of inorganic phosphate using varying levels of glucose-1-phosphate and constant concentration of AMP and glycogen | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase. |
| AID264487 | [1-3H]-2-deoxy-D-glucose uptake in 3T3 L1 adipocytes | 2006 | Journal of medicinal chemistry, May-04, Volume: 49, Issue:9 | Synthesis and structure-activity relationship study of antidiabetic penta-O-galloyl-D-glucopyranose and its analogues. |
| AID1186739 | Inhibition of glycogen phosphorylase a (unknown origin) | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Structure based inhibitor design targeting glycogen phosphorylase B. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl-β-d-glucopyranosylamines. |
| AID28957 | Partition coefficient (logP) | 2002 | Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1 | Rational determination of transfer free energies of small drugs across the water-oil interface. |
| AID1353852 | Inhibition of glycogen phosphorylase (unknown origin) | 2018 | European journal of medicinal chemistry, Mar-10, Volume: 147 | A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors. |
| AID1186738 | Inhibition of glycogen phosphorylase b (unknown origin) | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Structure based inhibitor design targeting glycogen phosphorylase B. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl-β-d-glucopyranosylamines. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||